Clinical Efficacy and Predictive Molecular Markers of Neoadjuvant Gemcitabine and Pemetrexed in Resectable Non-Small-Cell Lung Cancer

Documenti analoghi

• Phase II Trial of Induction Gemcitabine and Carboplatin Followed by Conformal Thoracic Radiation to 74 Gy with Weekly Paclitaxel and Carboplatin in Unresectable Stage III Non-small Cell Lung Cancer
  di: Bepler, Gerold, et al.
  Pubblicazione: (2011)
• Randomized International Phase III Trial of ERCC1 and RRM1 Expression–Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non–Small-Cell Lung Cancer
  di: Bepler, Gerold, et al.
  Pubblicazione: (2013)
• Thymidylate Synthase in Situ Protein Expression and Survival in Stage I Nonsmall-Cell Lung Cancer
  di: Zheng, Zhong, et al.
  Pubblicazione: (2008)
• Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma
  di: Creelan, Ben C., et al.
  Pubblicazione: (2013)
• Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non–Small-Cell Lung Cancer
  di: Haura, Eric B., et al.
  Pubblicazione: (2010)